WordNet

the 18th letter of the Roman alphabet (同)r
the 7th letter of the Roman alphabet (同)g

PrepTutorEJDIC

resistance / 17歳以下父兄同伴映画の表示 / rook
right hand

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 供血者の病歴 blood donor medical history
2. 成長ホルモンの生理学 physiology of growth hormone
3. 小児における成長ホルモン欠乏症の治療 treatment of growth hormone deficiency in children
4. 過渡期における成長ホルモン治療 growth hormone treatment during the transition period
5. 小児における成長ホルモン欠乏症の診断 diagnosis of growth hormone deficiency in children

English Journal

Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning.

Telegdy G, Schally AV.Author information Department of Pathophysiology, Neuroscience Research Group of the Hungarian Academy of Sciences, University of Szeged, Szeged, Hungary. telegdy@patph.szote.u-szeged.huAbstractThe antagonist MZ-4-71 of growth hormone-releasing hormone (GH-RH) has been shown to suppress the secretion of GH and insulin-like growth factor-1 (IGF-1), suggesting that this class of analogs could be used for the therapy of disorders characterized by excessive GH secretion. Numerous GH-RH antagonists has been synthetized and shown to suppress the growth of various tumors. MZ-4-71 facilitates the consolidation of passive avoidance learning. Beta-amyloid 25-35 impairs the consolidation of passive avoidance learning and MZ-4-71 fully blocks this impairment. However, little is known about the possible mechanism of action of GR-RH antagonists on these actions. In the present work, the possible effects of different neurotransmitters on the action of MZ-4-71 were studied in the memory consolidation of passive avoidance behavior. The involvement of cholinergic, serotonergic, dopaminergic, GABA-ergic, adrenergic and opiate receptors was tested. Mice were pretreated with a nonselective α-adrenergic receptor antagonist, phenoxybenzamine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a nonselective 5-HT2 serotonergic receptor antagonist, cyproheptadine, a nonselective muscarinic acetylcholine receptor antagonist, atropine, a D2, D3, D4 dopamine receptor antagonist, haloperidol, a γ-aminobutyric acid subunit A (GABA-A) receptor antagonist, bicuculline, or a nonselective opioid receptor antagonist, naloxone. Atropine, methysergide, cyproheptadine and naloxone prevented the effects of MZ-4-71 on passive avoidance learning, whereas haloperidol, phenoxybenzamine, propranolol and bicuculline did not change the effects of MZ-4-71. The results demonstrate that the muscarinic acetylcholine receptor, the 5-HT1/5-HT2 serotonergic receptor and opioid receptors are involved as mediators in the action of MZ-4-71 on the consolidation of passive avoidance learning.
Behavioural brain research.Behav Brain Res.2012 Aug 1;233(2):326-30. doi: 10.1016/j.bbr.2012.05.030. Epub 2012 May 26.
The antagonist MZ-4-71 of growth hormone-releasing hormone (GH-RH) has been shown to suppress the secretion of GH and insulin-like growth factor-1 (IGF-1), suggesting that this class of analogs could be used for the therapy of disorders characterized by excessive GH secretion. Numerous GH-RH antagon
PMID 22640814

Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice.

Telegdy G, Schally AV.Author information Department of Pathophysiology, Neuroscience Group of the Hungarian Academy of Sciences,University of Szeged, Szeged, Hungary. telegdy@patph.szote.u-szeged.huAbstractAntagonists of growth hormone-releasing hormone (GH-RH), such as MZ-4-71 suppress the secretion of GH. These findings suggest that GH-RH antagonists could be used for the therapy of disorders characterized by excessive GH secretion. It has been also demonstrated that MZ-4-71 displays antidepressant effects in a modified forced swimming test in mice, exerts anxiolytic effects in an elevated plus maze test, improves memory consolidation in passive avoidance learning, and corrects the impairment of memory consolidation caused by β-amyloid (25-35) in mice. However, little is known about the mechanisms of action of MZ-4-71 on brain functions. In the present work, the involvement of the adrenergic, serotonergic and GABA-ergic receptors in the anxiolytic action of MZ-4-71 was studied in an elevated plus maze. Mice were pretreated with a nonselective α-adrenergic receptor antagonist, phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist, prazosin, an α2-adrenergic receptor antagonist, yohimbine, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, and a γ-aminobutyric acid subunit (GABA-A) receptor antagonist, bicuculline. Phenoxybenzamine, prazosin, yohimbine, methysergide, cyproheptadine and bicuculline prevented the effects of MZ-4-71 on the elevated plus maze revealing that the anxiolytic actions of MZ-4-71 in this test are mediated, at least in part, by the an interaction of the α1/α2-adrenergic, 5-HT1/5-HT2 serotonergic and GABA-A-ergic receptors.
Behavioural brain research.Behav Brain Res.2012 Jul 15;233(1):232-6. doi: 10.1016/j.bbr.2012.04.011. Epub 2012 May 5.
Antagonists of growth hormone-releasing hormone (GH-RH), such as MZ-4-71 suppress the secretion of GH. These findings suggest that GH-RH antagonists could be used for the therapy of disorders characterized by excessive GH secretion. It has been also demonstrated that MZ-4-71 displays antidepressant
PMID 22569571

Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71.

Tanaka M, Schally AV, Telegdy G.Author information Department of Pathophysiology, Faculty of Medicine, University of Szeged, Szeged, Hungary.AbstractMZ-4-71 is an antagonist of growth hormone-releasing hormone (GH-RH) which suppresses the secretion of GH-RH. It has been shown that MZ-4-71 has antidepressive-like effects in a modified forced swimming test (FST) in mice, exerts anxiolytic effects in an elevated plus maze test, improves memory consolidation in passive avoidance learning, and corrects the impairment of memory consolidation caused by β-amyloid 25-35 in mice. However, little is known about the mechanisms of action of MZ-4-71 on brain functions. The involvement of the adrenergic, serotonergic, cholinergic, dopaminergic or GABA-ergic receptors in the antidepressant-like action of MZ-4-71 (1.0 μg/2 μl, intracerebroventricular (i.c.v.)) was studied in a modified mouse forced swimming test (FST). Mice were pretreated with a non-selective α-adrenergic receptor antagonist, phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist prazosin, an α2-adrenergic receptor antagonist, yohimbine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist methysergide, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, a non-selective muscarinic acetylcholine receptor antagonist, atropine, a D2, D3, D4 dopamine receptor antagonist, haloperidol or a γ-aminobutyric acid subunit A (GABA-A) receptor antagonist bicuculline. Phenoxybenzamine, prazosin, methysergide, cyproheptadine and atropine prevented the effects of MZ-4-71 on the immobility, the climbing and the swimming times. Yohimbine, propranolol, haloperidol and bicuculline did not change the effects of MZ-4-71. The results demonstrated that the antidepressant-like effects of MZ-4-71 in this modified mouse FST are mediated, at least in part, by the an interaction of the α1-adrenergic, 5-HT1/5-HT2 serotonergic, and muscarinic acetylcholine receptors.
Behavioural brain research.Behav Brain Res.2012 Mar 17;228(2):388-91. doi: 10.1016/j.bbr.2011.12.022. Epub 2011 Dec 19.
MZ-4-71 is an antagonist of growth hormone-releasing hormone (GH-RH) which suppresses the secretion of GH-RH. It has been shown that MZ-4-71 has antidepressive-like effects in a modified forced swimming test (FST) in mice, exerts anxiolytic effects in an elevated plus maze test, improves memory cons
PMID 22197299

Japanese Journal

先端巨大症 : 疫学・病態・診断(<特集>GH産生下垂体腺腫のupdate)

有田和徳,湯之上俊二,富永篤,栗栖薫
脳神経外科ジャーナル 16(9), 678-685, 2007-09-20
… (成長ホルモン〔GH〕産生下垂体腺腫)の発生数は,500人/年前後と推定される.先端巨大症の診断は,まずその特異な容貌に気付くところから始まるが,最近は糖尿病,不正咬合,夜間睡眠時無呼吸をきっかけに診断されることも多い.確定診断のためには,GHの過剰分泌,IGF-Iの高値,MRIによる下垂体腺腫の描出が必要である.GHの過剰は,経口糖負荷試験時のGH底値が1ng/ml以上 …
NAID 110006381197

Can We Predict Diabetic Complications by Examining GH Response to GH-RH Infusion Test in Patients with NIDDM?

IIZUKA TAKASHI,MIYAMOTO TERUO,ITO HIROKO,OMURA MASAO,NISHIKAWA TETSUO
Endocrine Journal 45(Suppl), S77-S80, 1998
NAID 130003549896

P-56 Immunohistochemical Detection of Rab 3 Protein in the Pituitary Glands of the Rat Species and the GH-RH Transgenic Rat

TAHARA Shigeyuki,SUGIYAMA Makoto,TAKUMI Ichiro,SANNO Naoko,TERAMOTO Akira,OSAMURA Yoshiyuki
Acta histochemica et cytochemica 31(2), 165, 1998
NAID 110003146959